Circulating cell-free DNA (cfDNA) is DNA released from necrotic or apoptotic cells into the bloodstream. While both healthy cells and cancer cells release cfDNA, tumors are associated with higher levels of tumor-derived circulating cell-free DNA (ctDNA) detectable in blood. Absolute levels of ctDNA and its genetic mutations and epigenetic changes show promise as potentially useful biomarkers of tumor biology, progression, and response to therapy. Moreover, studies have demonstrated the discriminative accuracy of ctDNA levels for diagnosis of gastrointestinal cancer compared with benign inflammatory diseases. Therefore, ctDNA detected in blood offers a minimally invasive and easily repeated ''liquid biopsy'' of cancer, facilitating real-time dynamic analysis of tumor behavior that could revolutionize both clinical and research practices in oncology. In this review, we provide a critical summary of the evidence for the utility of ctDNA as a diagnostic and prognostic biomarker in gastrointestinal malignancies. (Translational Research 2017;183:137-154) Abbreviations: cfDNA ¼ circulating cell-free DNA; ctDNA ¼ circulating cell-free tumor-derived DNA; NGS ¼ next generation sequencing; ALU ¼ short interspersed nucleic acid element repeats; LINE1 ¼ long interspersed nucleotide elements; RT-PCR ¼ reverse transcriptase polymerase chain reaction; CRC ¼ colorectal cancer; GIST ¼ gastrointestinal stromal tumor; HCC ¼ hepatocellular carcinoma
INTRODUCTION C
irculating cell-free DNA (cfDNA) is DNA released from necrotic or apoptotic cells into the bloodstream. [1] [2] [3] [4] [5] [6] While both healthy cells and cancer cells release cfDNA, tumors are associated with higher levels of cfDNA detectable in blood (average 180 ng/mL, ranging from 0 to .1000 ng/mL) compared with healthy controls (average 30 ng/mL, ranging from 0 to 100 ng/mL). 7 Within these ranges there is considerable variability between individuals, in part influenced by the underlying the inflammatory state. 7 cfDNA derived from tumor cells is termed circulating cell-free tumor DNA, or ctDNA. 2 cfDNA is highly fragmented and consists of short segments (,185-200 bp in length) 8, 9 which are generated by cellular apoptosis and long fragments (200bp-21 kbp) generated by necrosis, the latter being more prevalent in ctDNA in the presence of cancer.
ctDNA is, therefore, distinguishable from cfDNA using this method, as well as the presence of genetic alterations present in tumor cells, but not healthy cells. ctDNA is rapidly cleared from serum and plasma and therefore represents a highly dynamic marker of tumor biology. 10, 11 However, studies have shown that mutations detected in ctDNA do not correspond perfectly with those identified in primary tumor tissue DNA, particularly for early-stage tumors. Contributing factors to this current limitation in ctDNA detection are that copy numbers of ctDNA are generally very low compared with that of wild-type cfDNA, and limitations in the accuracy of current sequencing technologies limit the sensitivity for detecting specific mutations in cancer. 2, 12 In addition, tumor cells prone to release of ctDNA may be genetically different to the majority populations detected in the primary tumor due to genetic heterogeneity. 2 There are several ways in which cfDNA provides invaluable genomic data for clinical studies. Absolute levels of ctDNA and genetic point mutations within ctDNA detected using point mutation-targeted assays, whole exon genetic sequencing, or even whole genome sequencing techniques provide invaluable genomic data. In addition, epigenetic changes such as hypermethylation of CpG residues can also be determined. These alterations in ctDNA in blood at baseline and over time are potentially useful biomarkers of tumor biology, progression, and response to therapy. 2, 6 While evidence shows cfDNA levels are also elevated in inflammation 7, 13 and trauma, 14 several studies have demonstrated the discriminative accuracy of ctDNA levels in patients with gastrointestinal cancer compared with patients with benign inflammatory diseases. 3, [15] [16] [17] Therefore, ctDNA detected in blood offers a ''liquid biopsy'' of cancer, 4 potentially obviating the need for invasive tumor biopsy in some clinical scenarios and facilitating dynamic, repeated evaluations of tumor characteristics. 2, 7 Tumor biopsy is invasive, painful, and carries a risk to patients of complications such as bleeding and damage to neighboring structures. Moreover, tumor biopsies may only sample one area of tumor and miss important biological information due to tumor heterogeneity. Some tumors such as pancreatic cancer are difficult to access and therefore repeated sampling of tumors to monitor for prognostic mutations is not practical. Therefore, ctDNA has the potential to revolutionize both clinical management and research in oncology by offering patients a rapid, minimally invasive means of monitoring tumor behavior, 5 which through being more acceptable to patients, may also improve adherence to tumor management strategies. The noninvasive, easily repeatable nature of ctDNA detection also offers considerable benefits for largescale participation in gastrointestinal cancer research studies.
In this review, we provide a critical summary of the evidence for the utility of ctDNA as a diagnostic and prognostic biomarker in gastrointestinal malignancies.
METHODS OF QUANTIFYING CFDNA LEVELS, GENE MUTATIONS, AND GENE METHYLATION
Significant advancements have been made in cfDNA detection and quantification methods in recent years, and there are several excellent reviews and many papers describing the technical aspects of cfDNA quantification and ctDNA mutation detection to which we direct the reader. 2, 6, 7, [18] [19] [20] Methodology will, therefore, not be discussed in detail in this review. A brief summary of the process of cfDNA isolation, ctDNA mutation detection, and methylation pattern determination is provided in Fig 1. Briefly, cfDNA is isolated from plasma or serum and analyzed qualitatively using older fluorescence-based methods for cfDNA detection or increasingly by using quantitative and highly sensitive digital polymerase chain reaction (PCR). 7 Allele-specific targeted mutation analysis digital PCR methods allow detection of prespecified gene mutations to distinguish ctDNA from wild-type cfDNA, 21 while massively parallel sequencing microfluidic techniques and duplex sequencing coupled with next-generation sequencing (NGS) allow efficient and sensitive sequencing of the entire genome. 7, 20 It is possible to detect down to 0.01%-0.001% of mutation allele fractions using new methods. 20, 22 Short interspersed nucleic acid element (ALU) repeats and long interspersed nucleotide elements (LINE1) are noncoding repetitive DNA sequences distributed throughout the genome that are used to calculate the DNA integrity index in cfDNA. 7, 23 ALU115 fragments reflect cfDNA of healthy cell origin, whereas ALU247 fragments are more frequently detectable in ctDNA. 24, 25 This is an older method for distinguishing ctDNA from wild-type cfDNA which is less sensitive and is not widely used now because digital PCR techniques have improved sensitivity and specificity. Relative telomere length is another technique used infrequently in ctDNA studies, where the length of telomere repeat sequences distinguishes ctDNA from wild-type cfDNA. 26 DNA methylation modifies gene expression, genomic imprinting, and chromosome structure and stability. 27, 28 Methylation of cytosine residues in dinucleotide CpG sites is detected using bisulfite conversion 28, 29 and subsequent methylation-specific digital PCR (MSP). 30 Panels of methylation markers for use in MSP have been developed for gene mutations commonly found Fig 1. A, Development of cancer and relationship to circulating cell-free tumor DNA levels (ctDNA). ctDNA levels remain low in the healthy state. ctDNA levels increase with the presence of adenomas and become increasingly elevated with the progression of malignancy from carcinoma in-situ to early-stage cancer. Curative treatment causes a rapid fall in ctDNA levels back to baseline levels. However, ctDNA levels are detectable in recurrent disease and increase rapidly as advanced carcinoma and systemic metastases develop. B, The process of circulating cell-free tumor DNA (ctDNA) procurement, genetic analysis, and use in the clinic. A blood sample is taken from the patient in the clinic. Whole blood undergoes centrifugation and the plasma or serum supernatant is then isolated, applied to cfDNA isolation columns, and a multistep process of elution and precipitation of DNA from in malignancy, akin to what have been developed for gene mutation digital PCR.
DNA has also been isolated from free-circulating tumor cells in plasma to allow more specific clonal information about tumor cells independently of normal host cells. 2 However, this technique is beyond the scope of this review.
EVIDENCE FOR THE UTILITY OF CTDNA DETECTION FOR THE DIAGNOSIS AND MANAGEMENT OF GASTROINTESTINAL MALIGNANCIES
A landmark article by Bettegowda et al 6 evaluated the diagnostic utility of ctDNA in a number of different malignancies in a large sample of 640 patients. Their method used NGS of tumor tissue DNA to determine target mutations, which were then quantified in plasma ctDNA using RT-PCR. 6 Over 75% of patients with advanced-stage hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic cancer, and stomach and esophageal cancer had detectable ctDNA in plasma. 6 Of 223 patients without metastatic disease, ctDNA was detected in 73% of CRC, 57% of gastroesophageal cancers, and 48% of pancreatic cancers. 6 This article established the broad potential diagnostic utility of ctDNA across diverse gastrointestinal tumor types.
COLORECTAL CANCER
As the fourth most common malignancy with a global incidence of 17.2 cases per 100,000, CRC follows a stereotyped progression from premalignant polyp through to dysplasia, carcinoma in situ, and then carcinoma, associated with gradual accrual of genetic mutations. Stage I and II CRCs are usually curable and only metastatic, advanced stage IV disease has high mortality. Chromosomal instability with mutations in mismatch repair genes and loss of heterozygosity in the APC pathway are the most common mutations associated with adenoma development, with subsequent Kirsten rat sarcoma viral oncogene homolog protein (KRAS), BRAF, PIK3CA, PTEN, tumor protein 53 (TP53), BAX, and TGF-b mutations facilitating progression to carcinoma. 31 Currently, premalignant adenoma and carcinoma screening is performed by colonoscopy, which provides easy access to tumor tissue for genetic biomarker analysis. However, patient preference for blood-based testing instead of procedural screening tests and the drive for cost-effective CRC screening and diagnosis have led to much research into bloodbased biomarkers in CRC.
The greatest volume of evidence for the diagnostic and prognostic utility of ctDNA detection in gastrointestinal malignancy exists for CRC (Table I) .
DIAGNOSIS AND SCREENING IN CRC
Levels of both overall cfDNA and tumor-specific ctDNA have been shown in multiple studies to be higher in patients with CRC compared with healthy controls [32] [33] [34] [35] 41 and appear to distinguish early-stage tumors from benign lesions with considerable accuracy. 41, 42 In a study of 118 CRC patients, 49 with polyps, and 26 healthy controls, cfDNA levels had a diagnostic accuracy of 80% for early-stage CRC compared with benign gastrointestinal disease.
41
ALU247 fragment concentration is higher in plasma ctDNA from CRC patients compared with healthy controls. 23 A small pilot study reported the combination of Line 1, ALU 247, ALU 115, and mitochondrial DNA detection in plasma ctDNA had an AUC of 0.8 for CRC diagnosis alone, rising to 0.9 (positive predictive value of 81% and an negative predictive value of 74%) when combined with carcinoembryonic antigen (CEA) measurement. 78 A recent large study by Hao et al 79 of 205 patients with CRC, 63 with polyps, and 110 healthy controls found ALU115 and ALU247/115 ratio in ctDNA were significantly higher in CRC patients and patients with adenomas compared with healthy controls. Both levels fell after curative surgical resection. 79 KRAS mutations are common in CRC (40%-50%), 80, 81 occur early in the carcinogenic pathway 51 and have frequent mutation ''hotspots'' in codons 12 and 13, 44 making KRAS an attractive marker for CRC diagnosis. In a study of 58 patients with CRC, Lecomte et al 82 found that 78% of patients with CRC had detectable ctDNA; 38% had KRAS mutations in tumor specimens, in whom 45% also had these mutations detectable in ctDNA. 82 In a further study of 106 patients with metastatic CRC, Thierry et al 45 tested for 7 different common point mutations in the KRAS gene in plasma ctDNA and found 96% concordance between KRAS mutations in ctDNA and matched tumor specimens. 45 Sensitivity of detecting KRAS mutations in ctDNA plasma occurs. ctDNA is then quantified using real-time polymerase chain reaction (PCR). Specific gene mutations of interest are detected using allelic imbalance methodology, targeted PCR mutation assay, microarray of whole genome NGS. Hypermethylated CpG dinucleotides can be detected by bisulfite conversion of DNA. Briefly, bisulfite conversion protocols convert unmethylated, but not methylated, cytosine residues to uracil. The modified DNA is then analyzed using either MSP, whole genome sequencing, or methylation marker microarray panels. = was 92% and specificity was 98%. However, 2 small studies have demonstrated KRAS mutations in ctDNA in 35% (22 of 62) patients with benign colorectal disease 83 and 50% (2 of 4) of patients with long-standing ulcerative pancolitis, 64 raising concerns about specificity for CRC diagnosis but showing potential utility as a diagnostic tool for adenoma premalignant lesions. In the latter study, no correlation with mutations in primary tumor DNA was undertaken and no follow up of the patients with pancolitis was performed to determine outcome. This is a critical point as pancolitis is a strong risk factor for CRC, which is often sessile and difficult to diagnose. Moreover, others have found no evidence of KRAS mutations in ctDNA from patients with benign gastrointestinal diseases. 16 Mutations in the adenomatous polyposis coli (APC) gene are also common in CRC (60%-70%), occur early in carcinogenesis and over 80% occur in exon 15. 61 APC mutations in ctDNA significantly correlated with the stage of CRC disease in one study 62 ; however, mutations in the primary tumor were not evaluated. TP53 is also commonly mutated in CRC (60%-70%) 63, 66 ; however, it is a late event in CRC and there are no hotspot sites for mutation, making it a less useful marker for early diagnosis. 1 Studies suggest TP53 mutation detection rates of less than 15% in ctDNA; however, in those with known mutations in tumor, the detection rate is approximately 40%.
1,84 A small study reported BRAF1 mutations in ctDNA and matched primary tumor specimens from CRC patients compared with healthy controls. 85 This was confirmed by Thierry et al, 45 who found 96% concordance in BRAF mutations between ctDNA and tumor specimens. However, BRAF mutations do not occur frequently in early CRC and therefore may have limited diagnostic utility. Overall survival 30, 38 Disease stage 38, 39 Reduced survival after surgery 38, 39 Tumor recurrence after surgery 32, 33, 38 Response to neoadjuvant chemoradiation 40 DNA integrity index Diagnosis 23, 41, 42 Response to neoadjuvant chemoradiation 43 Abnormal gene methylation patterns are common in CRC and appear to be an early event in carcinogenesis, with good potential as biomarkers for diagnosis and screening. 54, 67 Around 25% of CRC tumors have evidence of gene hypermethylation and 40% of these are detectable in ctDNA.
KRAS
1 A small study compared overall ctDNA gene methylation between 24 CRC patients, 10 patients with benign gastrointestinal disease, and 56 healthy controls. 55 High levels of overall DNA methylation were seen in both CRC and benign colorectal disease, 55 demonstrating poor specificity of DNA methylation alone as a marker for CRC diagnosis.
Septin 9 (SEPT9) methylation in ctDNA is one of the best-validated biomarkers in CRC. SEPT9 methylation is present in over 90% of CRC specimens, and has been well validated in several large, well-designed studies using ctDNA, with a sensitivity of 68%-79.3% and specificity of 84.8%-89% for CRC diagnosis compared with healthy controls. [56] [57] [58] [59] 86 In several large studies, SEPT9 methylation in ctDNA is evident in 69%-88% of CRC, 30% of benign adenomas, and 8%-14% of healthy controls. 56, 59, 87 In another study of 92 CRC cases (25 stage I tumors and 67 stage II to IV tumors) and 92 controls, SEPT9 was positive in 96.4% of left-sided CRC and 94.4% of right-sided CRC. 56 By contrast, only 50% of right-sided tumors were detected using standard fecal-occult blood testing methods and 41.7% using CEA. This is clinically significant as right-sided tumors are more likely to be asymptomatic and missed by routine screening methods.
56
A well-designed study by Church et al 88 prospectively assessed the utility of methylated SEPT9 for CRC screening of a large cohort of 7941 asymptomatic individuals over 50 years of age using a commercial assay. A total of 53 patients were found to have CRC and methylated SEPT9 had sensitivity of 48.2% and specificity of 91.5% for overall diagnosis of CRC, with sensitivity values of 35.0%, 63.0%, 46.0%, and 77.4% for stage I-IV disease, respectively. 88 In addition, they found methylated SEPT9 only had 11.2% sensitivity for detection of advanced adenomas. 88 Others have shown SEPT9 is infrequently detected in adenomas greater than 1 cm in size (20%), and has lower sensitivity (14%) than stool DNA sensitivity (82%) for diagnosis of large adenomas in screening populations. 58, 87, 89 Another large study found stool DNA had greater sensitivity and specificity for CRC diagnosis than serum methylated SEPT9 in ctDNA. 89 These studies clearly demonstrate that SEPT9 alone is not a suitable screening marker for CRC, though it may have additional benefit in combination with other markers.
An interesting study by Ladabaum et al 71 evaluated the cost-effectiveness of SEPT9 as a screening blood test for CRC in comparison to current screening strategies, including fecal-occult blood testing, fecal immunohistochemical testing, sigmoidoscopy, and colonoscopy.
71 SEPT9 was cost-effective in comparison to no screening, but was inferior to other screening strategies. The cost-effectiveness of SEPT9 and similar ctDNA-based markers would improve if they increased uptake and longitudinal adherence to screening. 71 A large study by Lee et al 17 evaluated methylation patterns in 10 genes using matched primary tumor tissue and plasma ctDNA from 243 early-stage CRC cases, 64 patients with colonic adenomas and 276 healthy controls. They found aberrant gene methylation patterns in promoters of p14 (18%), p16 (34%), APC (27%), death-associated protein kinase (DAPK) (34%), helicase-like transcription factor (HLTF) (32%), human MutL homolog 1 (hMLH1) (21%), 0,6-methylguanine-DNA-methyltransferase (MGMT) (39%), retinoic acid receptor beta 2 (RARbeta2) (24%), Ras-association domain family member 2A (RASSF2A) (58%), and WNT inhibitory factor 1 (WIF1) (74%) in CRC patients compared with those with benign disease and healthy controls. 17 While the methylation score for each individual gene had a sensitivity of less than 40%, by using a diagnostic cut-off methylation score of 1.6 in a model that included APC, MGMT, RASSF2A, and WIF-1, the sensitivity of cfDNA methylation detection was 85.6% and specificity was 92.1% for CRC diagnosis, with a positive predictive value of 90.6% and a negative predictive value of 88.8%. 17 WIF-1, RASSF2A, p16, and HMLH1 hypermethylations in ctDNA of CRC patients have also been reported by others. 46, 72, 74, 75, 82, 90, 91 HMLH1 promoter hypermethylation appears to be an early event in carcinogenesis. 74, 90 Other research groups have also identified the hypermethylations of neuropeptide Y (sensitivity 97% and specificity 47%), proencephalin (95% sensitivity and 61% specificity), and neurogenin 1 (sensitivity 61%) in ctDNA as potential diagnostic markers of CRC. 46, 76 Leary et al 12, 20 described massively parallel sequencing and personalized analysis of rearranged ends in matched tumor and ctDNA specimens to identify somatic structural variants (including gene copy number alterations and rearrangements) for personalized cancer monitoring with greater sensitivity than other methods (0.001% variant detection in ctDNA). 20 While structural variants are rare in healthy cells and almost ubiquitous in cancer, they are highly unique between tumors and their utility is therefore confined to personalized tumor monitoring rather than diagnosis and screening.
Finally, microsatellite instability and loss of heterozygosity is a common feature in CRC and reflects defective DNA repair mechanisms. 60 Evidence of microsatellite instability is evident in plasma ctDNA in approximately 35% of CRC patients. 1 A small study found 16 of 27 (59%) patients who had CRC tumors with confirmed microsatellite instability also had detectable markers of microsatellite instability in ctDNA. 92 However, detection artifacts and high false positive rates for detection in ctDNA are likely to limit its utility as a diagnostic marker of CRC. 1 To summarize, these studies collectively demonstrate utility of both ctDNA levels and gene mutations for the diagnosis of CRC compared with the healthy state. However, noninvasive detection of colonic adenomas to triage the need for colonoscopic removal using ctDNA would also be desirable, and there is currently less evidence to support the utility of ctDNA techniques for distinguishing benign adenomas from the healthy state. Therefore, this should be an active area of research in future studies in CRC.
PROGNOSIS IN CRC
A small prospective study found KRAS mutations and RASSF2A hypermethylation in ctDNA were associated with reduced disease-free survival at 1 year in patients with metastatic CRC receiving chemotherapy. 91 A larger study of KRAS mutations in 58 patients reported that 2-year survival was only 48% in CRC patients with detectable plasma ctDNA compared with 100% in those without. 82 KRAS mutations in ctDNA have high diagnostic accuracy for CRC metastases, with a sensitivity of 87.2% and a specificity of 99.2. 6 A further small case-control study identified that TP53 mutations in cfDNA were associated with advanced clinical stage and liver metastases, but not lymph node metastases, tumor size, or vascular invasion. 84 Both TAC1 and SEPT9 gene methylation have prognostic utility in CRC. In a large study of 150 patients who underwent curative resection for CRC, methylated TAC1 and SEPT9 in serum ctDNA were independent predictors of tumor recurrence after surgery and cancerspecific mortality and were detectable in blood earlier than CEA levels. 73 In addition, hypermethylated HMLH1, HLTF, HPP1, and APC promoters in ctDNA are associated with reduced overall survival in CRC in several prospective studies. 39, 74, 75, 90 Others have also reported an association between HLTF and HPP1/TPEF hypermethylation and advanced tumor stage. 39, 75 Further large prospective studies are needed to validate the prognostic utility of gene alterations in ctDNA in CRC.
POST-SURGICAL RECURRENCE
Absolute levels of cfDNA predict survival after surgery in CRC, with lower pre-operative levels associated with greater survival. 38, 93 Plasma cfDNA levels rise steadily immediately after surgery, perhaps reflecting inflammatory responses. 35, 94 However, a rapid rise by day 3 postoperatively without a subsequent fall in levels is associated with tumor recurrence. 34, 35, 93 KRAS mutations and hypermethylation of p16 in ctDNA have both been associated with tumor recurrence after resection. 35, 77 In one study, the 2-year recurrence-free survival after curative resection was 66% in patients with detectable ctDNA levels compared with 100% in those without detectable ctDNA. 82 Importantly, one study showed only 3 of 16 CRC patients with postoperative tumor recurrence and KRAS mutation detection in ctDNA had elevated CEA levels, suggesting combining ctDNA gene mutation and CEA levels may improve sensitivity for postoperative recurrence detection.
In a well-designed small study of 11 CRC patients who had undergone curative resection by Reinert et al, 68 large somatic structural variants were identified in primary tissue specimens using NGS, then confirmed in plasma ctDNA using droplet-digital PCR. They demonstrated that ctDNA detection was useful postresection for determining the completeness of resection, response to adjuvant chemotherapy, recurrence after surgery, and development of metastases. 68 Importantly, using this method allowed early and highly accurate diagnosis of recurrence prior to conventional techniques of tumor recurrence surveillance (both sensitivity and specificity were 100%). For metastatic disease, detection was an average of 10 months earlier than conventional follow up. 68 Taback et al 52 described an interesting technique to improve the accuracy of ctDNA as a prognostic marker after resection, by isolating ctDNA from mesenteric venous samples taken during surgical resection, the hypothesis being that ctDNA levels may be higher in mesenteric venous samples due to CRC venous drainage via the mesenteric and portal systems. They confirmed that gene hypermethylation was more commonly detected in mesenteric (11/11) compared with peripheral plasma samples (9/11). 52 This novel technique is straightforward to use during surgery and requires validation in larger studies.
CHEMOTHERAPY RESPONSE AND RESISTANCE
One of the most exciting applications of ctDNA is for determining tumor treatment response and resistance to chemotherapy. KRAS and EGFR mutations conferring resistance to EGFR inhibitors can be detected in ctDNA of patients who are failing EGFR inhibitor therapy. 6, 95 KRAS and BRAF mutations measured in ctDNA prior to therapy and quantification of levels during therapy with cetuximab and irinotecan predict response to therapy 53, 96 and these mutations are detectable prior to radiological evidence of tumor progression. 53, 97, 98 Though correlation between BRAF mutations in ctDNA and tumor specimens is high, studies have generally found BRAF mutations to be rarely detected in tumor specimens of CRC patients, which limits its clinical utility compared with KRAS. 40, 41, 96 A recent large study of 503 patients with CRC by Tabernero et al 40 confirmed the utility of detecting KRAS, BRAF, and PIK3CA mutations in ctDNA in CRC patients on regorafenib therapy and demonstrated that mutations present in ctDNA change dynamically during chemotherapy treatment and may differ to those present in baseline, pretreatment tumor samples.
Similarly, overall cfDNA levels have also been used to assess response to neoadjuvant chemoradiation in rectal carcinoma. Responders have a significant reduction in plasma cfDNA levels after treatment compared with nonresponders. 43 DNA integrity index in cfDNA, measured by ALU repeats, is also an independent predictor of response to neoadjuvant chemoradiation. 99 In summary, there is good evidence from large validation studies that methylated SEPT9 and KRAS mutations in ctDNA are useful and accurate markers for CRC diagnosis, prognosis including detection of metastatic disease, and for rapid detection of postsurgical recurrence. KRAS mutations additionally predict response to EGFR-based biologic agents. Methylated RASSF2A, HMLH1, and WIF-1 may also prove useful for diagnosis. Though few studies have specifically evaluated the utility of ctDNA in CRC for distinguishing patients with metastatic disease, pilot data suggest potential utility of ctDNA for metastatic disease detection in CRC. The time is ripe for further studies validating the costeffectiveness of these markers within current management guidelines. However, available data suggest current test sensitivity is inadequate for their use as sole screening markers in CRC compared with current screening strategies. Studies validating of combinations of biomarkers with CEA and further assessment of the impact if blood-based biomarkers on CRC screening uptake and follow up are urgently needed.
ESOPHAGEAL CARCINOMA
Incidence of esophageal cancer is 5.9 per 100,000 globally 100 and it has 5-year survival rates of only 17% despite treatment. The majority of esophageal carcinomas are adenocarcinoma (10%) or squamous cell carcinoma (90%). Barrett's esophagus, metaplasia induced by chronic reflux esophagitis, represents the premalignant lesion in adenocarcinoma. 101 Adenocarcinoma incidence and mortality have been steadily increasing over the last decade. The most common genetic mutations in esophageal cancer are TP53, CDKN2A, SMAD4, and ARID1A in adenocarcinoma and TP53, retinoblastoma 1 (RB1), CDKN2A, PIK3CA, and NOTCH1 in squamous cell carcinoma. 101 Diagnosis and screening in Barrett's esophagus is by gastroscopy, which has a low complication rate and allows simultaneous treatment options for many lesions and ready access to genetic material. However, preference for noninvasive approaches to screening and monitoring and a lack of other biomarkers provide a potential role for ctDNA in esophageal carcinoma management.
To date, there have only been a handful of small casecontrol studies evaluating the clinical utility of cfDNA and ctDNA in esophageal carcinoma. These are summarized in Table II .
DIAGNOSIS AND SCREENING OF ESOPHAGEAL CARCINOMA
Zhai et al 102 conducted genome-wide sequencing in cfDNA and matched tumor specimens in a small casecontrol study of 28 patients (8 with esophageal carcinoma, 10 with Barrett's esophagus, and 10 healthy controls). They found that ctDNA gene methylation profiles correlated significantly (r 5 0.92) with methylation profiles of the primary tumor and identified differences in genetic profiles between esophageal carcinoma, Barrett's esophagus, and healthy controls. 102 This requires further exploration in larger cohorts.
DISEASE PROGNOSIS AND SURVIVAL IN ESOPHAGEAL CARCINOMA
Hypermethylation of the MutS homolog 2 (MSH2) promoter was identified in primary tumor specimens of 101 of 209 patients (48%) with esophageal squamous cell carcinoma, of which 77 patients (76%) had matching findings in plasma ctDNA. MSH2 hypermethylation detected in plasma ctDNA predicted reduced diseasefree survival after esophagectomy in one study, 103 while another reported APC hypermethylation in ctDNA was associated with reduced survival in esophageal adenocarcinoma, but was not commonly detected. 104 Both studies were small and had no adjustment for confounding variables.
Current data are insufficient to define the role of ctDNA in esophageal cancer diagnosis and management and further studies are warranted.
GASTRIC CANCER
The global incidence of stomach cancer is 12.1 cases per 100,000 person-years at risk. 100, 105 Early-stage tumors are curable by resection; however, locally advanced disease has only 25%-25% 5-year survival and most patients with metastatic disease survive less than 12 months despite treatment. 105 Common genetic alterations in sporadic gastric cancer include altered methylation pattern of the mismatch repair genes and mutations in TP53 and HER2/ERBB2/EGFR pathways, whereas hereditary cancer syndromes including gastric cancer include mutations in APC, TP53, STK11, CDH1, and CTNN1A. 105 As these mutations represent therapeutic targets with available treatments, ctDNA could prove useful for identifying patients most likely to respond to systemic targeted therapies or early detection of drug resistance mutations.
DIAGNOSIS OF GASTRIC CANCER
A summary of current data of blood-based biomarkers in gastric cancer is found in Table II . cfDNA levels are significantly higher in patients with gastric carcinoma compared with healthy controls. 106, 107 Kim et al 108 found that cfDNA levels had a sensitivity of 96.67% and a specificity of 94.11% for diagnosis of gastric cancer compared with healthy controls when a cut-off of 90 ng/mL was used; however, cases were not earlystage tumors and the sample size was also small.
Studies have found significant associations between gastric cancer and promoter hypermethylation of the XIAP association factor 1 (XAF1), APC, HMLH1, and tissue inhibitor of metalloproteases 3 (TIMP3) genes detected in ctDNA. 109, 111 XAF1 plays a tumor suppressor role in carcinogenesis and is frequently downregulated in gastric carcinoma specimens.
109
XAF1 promoter hypermethylation in ctDNA had reasonable accuracy for diagnosis of gastric cancer from healthy controls (AUC of 0.9) and the levels correlated with shorter overall survival in a study. 109 Another study reported 33 of 60 cancer subjects (55%) and 3 of 22 healthy controls (14%) had detectable target gene methylation in serum. 111 Promoter methylation was detected for APC in 17%, E cadherin in 13%, HMLH1 in 41%, and TIMP3 in 17% of gastric cancer subjects. 111 Furthermore, methylated APC, HMLH1, and TIMP3 concentrations were significantly associated with stage III and stage IV diseases, 111 whereas E cadherin and APC combined were associated with shorter overall survival. 111 However, of concern in this study was the Abbreviations: APC, adenomatous polyposis coli; ctDNA, cell-free DNA; HML1, human Mut-L homolog 1; MINT2, multimodular adaptor protein 2; MSH2, MutS homolog 2; PDGFR, platelet-derived growth factor receptor; RASSF1A, Ras-association domain family member 1a; SOX17, sexdetermining region Box 17; TIMP3, tissue inhibitor of metalloproteases 3; XAF1, XIAP association factor 1.
relatively high detection of methylated target genes in the healthy control group. This may reflect the underlying predisposition to gastric cancer and therefore poor specificity of ctDNA for gastric cancer diagnosis. 111 In addition, ctDNA findings were not confirmed in primary tumor specimens. Another study highlighted increased sex determining region Box 17 (SOX17) promoter methylation in gastric carcinoma, with a trend to shorter overall survival. However, this study was small and included no controls. 110 RASSF1A promoter methylation in ctDNA was also identified in 34% of 47 patients with gastric adenocarcinoma compared with 3% of 30 patients with benign gastric disease and 30 healthy controls (P , 0.001), suggesting potential utility as a diagnostic marker for gastric carcinoma. 72 ctDNA RASSF1A methylation correlated strongly with RASSF1A methylation in tumor specimens. 72 Multimodular adaptor proteins, or MINTs, are members of the X11 family and have key roles in cell membrane function and cellular transport. Methylation of MINT2 promoter was detected in ctDNA of 39% of 92 patients with gastric carcinoma, 6% of 48 patients with chronic gastritis and no healthy controls. 112 The findings in ctDNA were confirmed in matched primary tumor specimens. MINT2 methylation was significantly associated with tumor progression, metastatic disease, and shorter overall survival, making this a potentially valuable diagnostic and prognostic biomarker that warrants further study.
POST-SURGERY PROGNOSIS AND RECURRENCE DETECTION IN GASTRIC CANCER
Levels of cfDNA fall rapidly after surgery for gastric carcinoma and recurrent levels of detectable ctDNA have been associated with tumor recurrence. 108 More specifically, others have demonstrated that detectable XAF1 methylation in serum ctDNA after resection for gastric carcinoma is associated with tumor recurrence. 109 
GASTROINTESTINAL STROMAL TUMORS (GIST)
Several groups have evaluated ctDNA mutation detection as a diagnostic and prognostic marker for GIST tumors; however, studies have been small and require validation. Maier et al 113 found that cKIT and platelet-derived growth factor receptor A mutations in ctDNA were common in GIST compared with healthy controls. Moreover, mutation concentration in ctDNA was higher in patients with active disease compared with those in clinical remission or who responded to therapy. Rawnaq et al 114 assessed loss of heterozygosity in 12 polymorphic marker regions in 91 patients with recurrent GIST. They found microsatellite instability in ctDNA in 33% (30 of 92) patients with recurrent disease. 114 However, confounding factors such as age and duration of follow up were not considered. Another very small study by Yoo et al 115 identified cKIT mutations in exon 17 which predicted the response to tyrosine kinase inhibitorbased chemotherapy regimens in GIST patients.
In gastric carcinoma, current evidence suggests XAF1, HMLH1, RASSF1A, APC, and TIMP3 methylations are potential diagnostic markers, while XAF1 is also useful for postsurgical recurrence detection. Methylated MINT2 appears to have both prognostic and diagnostic utility in gastric carcinoma, including detection of metastatic disease. Further studies validating these markers and defining their clinical role are needed.
PANCREATIC CANCER
Pancreatic cancer accounts for 2% of cancers globally with a stable incidence of 1-10 per 100,000 people. 100, 116 It is the eighth most common cause of cancer-related death with 5-year survival rates of only 5% as it is frequently clinically silent until very advanced, when curative therapies are often no longer. 117 Pancreatic cancer progresses from premalignant lesions to cancer in a similar molecular fashion to CRC. More than 90% have KRAS mutations of which 80% are in exon 12.
118-121 Other common rate-limiting mutations as lesions progress include CDKN2A, TP53, and SMAD family 4 (SMAD4) mutations. 116 Currently, there is no effective screening tool for premalignant lesions or pancreatic cancer. 116 Obtaining pancreatic tissue for diagnosis and genetic biomarkers is difficult as it requires either endoscopic ultrasound-guided biopsy with an associated risk of tumor seeding; therefore, there is a potential role for ctDNA to reduce the need for invasive pancreatic biopsy.
The discovery of identical KRAS mutations in both pancreatic tumor specimens and ctDNA by Sorenson et al 122 was a pioneer publication in ctDNA research. Their findings have been confirmed by various groups. A recent article by Kinugasa et al 121 shows that in 75 patients with pancreatic cancer demonstrated KRAS mutations were detected in 74.7% of tumor specimens and 62.6% of ctDNA samples. Survival was reduced in those with KRAS mutations identified in ctDNA, but not in tissue samples. 121 Another study of 47 patients with pancreatic cancer and 31 patients with chronic pancreatitis reported 47% detection of KRAS mutations in ctDNA in pancreatic cancer patients, compared with 13% in patients with chronic pancreatitis, with a sensitivity of 47% and specificity of 87% for cancer diagnosis. 15 However, combining KRAS mutation detection in ctDNA with CA19-9 had a sensitivity of 98%, a specificity of 77%, and a negative predictive value of 96%. 15 Interestingly, none of the 4 patients with chronic pancreatitis went on to develop pancreatic cancer in 36 months of follow up. This study highlights that ctDNA KRAS detection may be a useful adjunct to CA19-9 testing when CA19-9 results are equivocal. 15 Liggett et al 117 used a microarray methylation detection method for 56 fragments (MetDet56) and found that methylation patterns in 8 gene promoter regions could reliably distinguish pancreatic cancer from healthy controls, with a sensitivity of 82% and a specificity of 78%. 117 These genes included breast cancer-associated gene 1 (BRCA1), cyclin D2 (CCND2), HMLH1, cyclin-dependent kinase inhibitor 1C (CDKN1C), progesterone receptor (PGR) distal, PGR proximal, spleen tyrosine kinase (SYK), and Von Hippel-Lindau (VHL). 117 A second panel of 14 gene promoter regions could distinguish pancreatic cancer from chronic pancreatitis with a sensitivity of 91% and a specificity of 91%. 117 These genes included CCND2, death-associated protein kinase 1, estrogen receptor 1, PromA, HMLH1, MGMT, Mucous gel forming protein 2 (MUC2), myogenic differentiation 1, CDKN2B, CDNK1C, phosphoglycerate kinase 1 (PGK1), PGR proximal, RARbeta, retinoblastoma 1 (RB1), and SYK.
117 CDKN1C, CCND2, HMLH1, PGR proximal, and SYK were identified in both panels and therefore may provide a simple broad marker panel worthy of validation for pancreatic cancer diagnosis. 117 In this study, ctDNA gene mutations were not compared with those present in the primary tumor.
Yi et al 123 reported a sensitivity of 81% and a specificity of 95% for the combination of methylated basonuclin 1 (BNC1) and ADAM metallopeptidase with thrombospondin 1 (ADAMTS1) in ctDNA for diagnosing early-stage pancreatic carcinoma, including pancreatic in situ neoplasia 3. 123 Other small studies have reported abnormal methylation of the CCDN2, Von Hippel-Lindau, thrombospondin 1 (THBS1), suppressor of cytokine signaling 1 (SOCS1), and plasminogen activator and urokinase (PLAU) genes in pancreatic cancer. 124 In summary, KRAS mutations in ctDNA appear useful for diagnosis of pancreatic cancer and can distinguish from chronic pancreatitis, which addresses an important clinical diagnostic need. However, detecting combinations of KRAS mutations with other biomarkers may improve early-stage diagnostic accuracy of ctDNA and validation studies are needed.
HEPATOCELLULAR CARCINOMA
As the sixth most common malignancy worldwide and the third most common cause of cancer-related death, HCC has a high mortality despite treatment. 100, 125 HCC usually develops within a background of liver disease, usually in the presence of cirrhosis. Due to the many potential predisposing etiologies of liver disease, HCC is genetically heterogeneous and involves many molecular carcinogenic pathways. Commonly mutated genes include CTNNB1/APC/AXIN1, TERT, CDKN2A, PIK3CA, TP53, and ARID1 and ARID2. 126 To date, this has been a key limitation in the translation of genetic markers in HCC to clinical care. Currently, HCC screening is performed twice yearly using ultrasound, and diagnosis does not require tumor tissue biopsy. 125 Therefore, ctDNA would provide an alternate means of obtaining genetic information about the tumor in the absence of liver biopsy.
There have been several studies evaluating cfDNA and ctDNA utility in HCC management. A summary of available ctDNA data in HCC is found in Table III .
DIAGNOSIS AND SCREENING IN HCC
Currently available tumor markers for HCC show only moderate sensitivity and specificity for HCC. Several studies show that cfDNA levels are significantly higher in patients with HCC compared with chronic liver disease and healthy controls and reasonable accuracy for distinguishing between HCC and chronic liver disease, [128] [129] [130] [131] 133, 139 with reported sensitivity of 56.4%-69.2% and specificity of 93.3% 128, 130 In these studies, attempts to distinguish ctDNA from cfDNA were not made.
El-Shazly et al 134 found longer cfDNA fragments were more common in HCC cases compared with healthy controls, with DNA integrity more strongly associated with HCC diagnosis than cfDNA concentration. 134 An interesting study by Fu et al 26 found that the relative telomere length in serum cfDNA was significantly higher in 140 Hepatitis B (HBV)-related HCC cases without cirrhosis compared with 280 HBVinfected noncirrhotic controls and this remained significant on multivariate analysis. 26 The large sample size and statistical adjustment for clinical confounders make this a strong study design and further assessment of telomere length in cfDNA in noncirrhotic HCC should be prioritized.
While gene mutations are very common in HCC, they are highly varied, with most gene alterations reported in less than 30% of tumors and few ''hotspots'' of frequent mutation. Tumor suppressor TP53 249Ser is an exception, a ''hotspot'' mutation very commonly associated with aflatoxin exposure, HBV infection, and HCC. It occurs predominantly in South Asia and sub-Saharan Africa, where exposure to aflatoxin through groundnut consumption is high. 131 However, this mutation is very uncommon in Caucasian HCC populations. 131, 135 There are several high-quality genetic epidemiology studies published by Kirk et al 131, 136 demonstrating a strong association between ctDNA TP53 mutation Ser249 and HBV-related HCC in Gambians and this correlates closely with serum aflatoxin adduct levels. 131, [136] [137] [138] The largest of these studies detected the mutation in 74 of 186 HCC cases, 15 of 98 patients with HBV-related liver cirrhosis, and 12 of 348 HBV-infected controls, with an odds ratio of 20.3 for HCC. 131 This study was particularly important for highlighting the potential utility of ctDNA for diagnosis of HCC in resource-poor settings. However, mutations that predispose to HCC and predate HCC development are unlikely to be highly specific for HCC diagnosis and may be better suited to HCC risk stratification for the purposes of screening. This study also described confounding adjacent gene mutations that affected the accuracy of TP53 249Ser mutation assays, highlighting an important potential cause of reduced diagnostic sensitivity of ctDNA point mutation analysis for HCC diagnosis. 131 There have been few other studies of ctDNA gene mutations in HCC. An Egyptian case-control study reported low levels of TP53 detection and an absence of CTNNB1 mutations in ctDNA of HCC patients of mixed etiology, and these findings were confirmed in primary tumor tissue specimens in a smaller subset of patients. 139 Promoter methylation of RASSF1A occurs in up to 70% of HCC patients compared with patients with chronic liver disease and healthy controls (6%-8% RASSF1A hypermethylation). 30, 127, 132, 140, 141 Importantly, several groups have found elevations in methylated RASSF1A and p15 and p16, APC, fragile histidine triad (FHIT), and E cadherin 30, 142 in ctDNA predates HCC diagnosis. 30, 141 Overall accuracy of RASSF1A, p15, and p16 methylation detection in ctDNA for HCC diagnosis was 89% (sensitivity of 84% and specificity of 94%), after adjusting for confounding variables. 30 Hypermethylation of G protein-coupled bile acid receptor GPBAR1 (TGR5) in ctDNA was significantly more common in HCC cases (77/160) compared with chronic HBV infection (12/88) and healthy controls (2/45) in one large study. 143 When combined with alpha-fetoprotein, TGFR5 significantly improved sensitivity for diagnosis of HCC (81.25% for AFP cut-off of 20 ng/mL); however, this was at the expense of reduced specificity (38.64%). Interestingly, there was significantly greater methylation in those over 60 years of age, confirming the importance of adjusting for confounding factors such as age in gene methylation studies. 143 By contrast, hypomethylation of LINE1 repeats in ctDNA is more common in HCC cases compared with cirrhosis and healthy controls, though diagnostic accuracy has not been assessed. 24 
PROGNOSIS IN HCC
Several studies have reported significant associations between overall cfDNA levels and tumor differentiation and tumor size, 130, 144 as well as a negative association with 3-year disease-free survival. 144 In a large study of 87 HCV-related HCC patients with chronic HCV infection, Tokuhisa et al 129 found that high cfDNA levels were an independent predictor of shorter overall survival and distant metastases after hepatectomy on multivariate analysis. However, in another cohort of 96 HCV-related HCC and 99 chronic HCV controls not undergoing surgery, the same group found no association between High CLIP score 24 Microsatellite instability marker D8S258
Overall survival cfDNA levels and tumor size, stage, or overall prognosis. 133 Interestingly, they found that cfDNA levels correlated with inflammatory cytokine gene expression. 133 Hypomethylation of LINE1 repeats in ctDNA was an independent predictor of shorter overall survival and is associated with HBV infection, large tumor size, and advanced CLIP score in a study. 24 High DNA integrity has also been shown to be an independent marker of shorter overall survival, tumor size, TMN stage, vascular and lymphatic invasion, and distant metastases. 134 Two markers of microsatellite instability D8S258 and D8S264, in combination with ctDNA concentration, were independent predictors of overall and 3-year disease-free survival in HCC. 145 Moreover, D8S258 was independently associated with tumor stage, tumor differentiation, and vascular invasion. 145 To summarize, available evidence suggests that concentration of overall cfDNA and TP53 249Ser mutations in ctDNA are important diagnostic markers of advanced-stage HBV and aflatoxinrelated HCC in African patients, but not in Caucasians. cfDNA levels appear prognostic for both advanced disease stage and metastases, whereas RASSF1A, p15, and p16 methylations appear promising diagnostic markers for early-stage HCC. It is important to note that few large validation studies have been conducted of ctDNA in HCC patients. Future studies should also include subanalyses of different etiologies of HCC.
CONSIDERATIONS FOR THE DESIGN OF FUTURE STUDIES
There are 3 main limitations common to many studies investigating ctDNA detection in gastrointestinal malignancy. The first is lack of a standardized approach to isolation, detection, and quantification of cfDNA levels or gene mutations and epigenetic changes in ctDNA. The concentration of cfDNA is higher in serum than plasma due to release from cells during coagulation [146] [147] [148] [149] [150] ; however, both methods are widely used and results are not comparable. Furthermore, while DNA is relatively robust, studies have demonstrated degradation in sample quality over time and the use of historical samples may reduce accuracy for cfDNA quantification and analysis and likewise reduce comparability across studies. 148, 151, 152 Studies validating different techniques in parallel are needed.
Second, not all studies have determined the gene mutation and gene methylation patterns in both ctDNA and matched primary tumor specimens, and few have compared ctDNA sequence to germline sequence in nontumor cells within the same subject. For diagnosis, genetic variants ideally must only be present in ctDNA, not cfDNA from healthy cells. For prognosis, ctDNA must accurately reflect mutations currently present in the primary tumor. These comparisons are essential to establish credibility of ctDNA as a dynamic marker of tumor.
The third criticism of many published studies in this field is their small sample size, which limits discriminative power to determine the effects of clinical confounding variables. For example, studies have shown DNA methylation is independently influenced by age, smoking, alcohol consumption, gender, toxin exposure, diet (particularly folate intake), physical activity, BMI, 153 and even socioeconomic status. 28, 36, 47, 48, 65, 154 Background polymorphisms can also affect epigenetic methylation and tumor phenotype and should be accounted for. 69 The etiology of underlying disease may also be a factor influencing the carcinogenesis pathway through altered inflammatory mechanisms. Detailed analysis of these potentially important clinical variables cannot be performed rigorously without sufficient numbers of subjects included. Indeed, development of strict statistical analysis benchmarks for studies in ctDNA akin to bioinformatical analysis standards developed for GWAS studies would greatly benefit this field.
FUTURE DIRECTIONS FOR THE PRACTICAL USE OF CTDNA TECHNIQUES IN THE CLINIC
Collectively, these data support a potential role for ctDNA at the bedside in gastrointestinal malignancy. ctDNA levels and mutation detection has proven utility for diagnosis in gastrointestinal malignancy, including more limited evidence for diagnosis of premalignant lesions for some cancers (such as colonic adenomas and Barrett's esophagus) which could allow a screening blood test to triage the need for more invasive endoscopy to detect and remove premalignant lesions. Prognostic information offered by ctDNA mutation detection could facilitate early detection of metastatic disease and personalize treatment algorithms to maximize outcomes. ctDNA also provides rapid detection of tumor recurrence after curative therapy, with evidence for this in CRC and HCC. Identification of systemic treatment resistance-conferring genetic mutations in ctDNA also has proven utility in CRC. Moreover, development of epigenetic methylation inhibitor therapies means ctDNA gene methylation detection may also become an important biomarker for prognosis and treatment response. Genetic mutations and altered methylation patterns have proven useful for prognosis in CRC, pancreatic cancer, and HCC, whereas to date methylation changes have been the main biomarker identified in ctDNA in gastroesophageal cancer.
From a practical perspective, there are still limitations to the use of ctDNA in the clinic. Cost of whole exome sequencing is currently very high and unlikely to be a cost-effective approach in the short term. Moreover, limitations in sensitivity for detecting the majority of mutations present in primary tumor tissue in ctDNA still exist, as outlined in many of the studies described, particularly for early-stage disease and welldifferentiated tumors with lower metastatic potential such as HCC. However, the rapid pace of genomic technology and associated bioinformatics analysis platform developments, coupled with subsequent reductions in sequencing costs over time, mean it is likely that these barriers will be overcome and targeted whole exon sequencing will become more readily available, with lower detection limits and greater sensitivity and specificity for ctDNA detection. Whole exon sequencing will also expand the clinical utility of ctDNA in malignancies with greater heterogeneity of genetic mutational sequences such as HCC, where individual targeted point mutation assays are unlikely to be helpful. However, for malignancies such as CRC, targeted combinations of point mutation in panels are likely to prove very useful for both diagnosis and prognosis. Targeted mutation assays are also likely to have an important role for following individual mutations located in tumor specimens over time for early detection of recurrence after curative therapies. While in CRC the mutational landscape is well recognized and the future looks bright for translation of ctDNA-based technologies into the clinic, for other malignancies such as HCC and esophageal cancer more research is still required to identify the best genetic biomarkers for diagnosis and prognosis. Arguably, where ctDNA will prove most clinically useful will be malignancies such as HCC and pancreatic cancer, where tumor tissue is not routinely obtained or is not recommended due to the potential for tumor seeding of biopsy tracts. Finally, how we successfully combine biomarkers spanning genomics, metabolomics, and proteomic domains and incorporate them into current gastrointestinal malignancy screening and management guidelines to maximize early cancer diagnosis and prognosis remains a critically important future challenge for translational researchers. Greater translational data quality and cost-effectiveness analyses will support regulatory changes to allow incorporation of these exciting new technologies at the bedside.
CONCLUSION
There is a wealth of data supporting the utility of ctDNA for both diagnosis and prognosis in various gastrointestinal malignancies, with particularly strong evidence for diagnosis and prognosis in CRC, pancreatic cancer, and HCC. Monitoring for tumor recurrence after surgery and detection of mutations indicating resistance to chemotherapy are two of the most promising clinical uses of ctDNA detection. Pilot data also support a role for ctDNA in metastatic disease detection in CRC, gastric cancer, and HCC. However, few studies have specifically evaluated the accuracy of ctDNA techniques for distinguishing metastatic from nonmetastatic disease with sufficient power. Further large-scale validation studies of ctDNA biomarkers will help refine their role in the clinical management of gastrointestinal malignancies.
